Mary Collier
Impact in
- Oncology top 10%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
-
- Breast Cancer Treatment Studies
Papers in
- Oncology 15
- Cancer Treatment and Pharmacology 8
- Colorectal Cancer Treatments and Studies 4
- HER2/EGFR in Cancer Research 3
- Peptidase Inhibition and Analysis 3
-
- Advanced Breast Cancer Therapies 3
- Co-authors
- Neil J. Clendeninn (8 shared papers)Anthony Elias (4 shared papers)Xin Huang (3 shared papers)Lynn G. Feun (4 shared papers)Kathy D. Miller (4 shared papers)Linda J. Paradiso (4 shared papers)Kenneth A. Kern (3 shared papers)Yazdi K. Pithavala (5 shared papers)
- Journals
- Journal of Clinical Oncology (6 papers)Investigational New Drugs (3 papers)Cancer (2 papers)Annals of Oncology (2 papers)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Mary Collier
26 papers receiving 573 citations
Peers
Comparison fields: 5 of 61
- Oncology 294
- Cancer Research 117
- Pulmonary and Respiratory Medicine 135
- Hematology 40
- Molecular Biology 213
Countries citing papers authored by Mary Collier
This map shows the geographic impact of Mary Collier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Collier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Collier more than expected).
Fields of papers citing papers by Mary Collier
This network shows the impact of papers produced by Mary Collier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Collier. The network helps show where Mary Collier may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary Collier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 75 | |
| 2 | 2005 | 60 | |
| 3 | 1993 | 51 | |
| 4 | 2009 | 44 | |
| 5 | 2004 | 41 | |
| 6 | Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. | 2000 | 36 |
| 7 | 1997 | 35 | |
| 8 | 2006 | 35 | |
| 9 | 1991 | 32 | |
| 10 | 2006 | 24 | |
| 11 | 1989 | 23 | |
| 12 | 2001 | 23 | |
| 13 | 1991 | 16 | |
| 14 | 1991 | 15 | |
| 15 | 1992 | 15 | |
| 16 | 2000 | 14 | |
| 17 | 1994 | 13 | |
| 18 | 1994 | 9 | |
| 19 | 2010 | 7 | |
| 20 | 2005 | 7 |
About Mary Collier
Mary Collier is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Infectious Diseases, having authored 26 papers that have together received 597 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (4 papers), Advanced Breast Cancer Therapies (3 papers), HER2/EGFR in Cancer Research (3 papers), Peptidase Inhibition and Analysis (3 papers), Head and Neck Cancer Studies (2 papers), HIV/AIDS drug development and treatment (2 papers) and Protease and Inhibitor Mechanisms (2 papers). The work is most often cited by research in Oncology (294 citations), Cancer Research (117 citations), Pulmonary and Respiratory Medicine (135 citations), Hematology (40 citations) and Molecular Biology (213 citations). Mary Collier has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Neil J. Clendeninn, Anthony Elias, Xin Huang, Lynn G. Feun, Kathy D. Miller, Linda J. Paradiso, Kenneth A. Kern, Yazdi K. Pithavala, Leslie R. Laufman and Wayne D. Brenckman. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.